» Articles » PMID: 20653983

Preventive Effects of Chronic Exogenous Growth Hormone Levels on Diet-induced Hepatic Steatosis in Rats

Overview
Publisher Biomed Central
Date 2010 Jul 27
PMID 20653983
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-alcoholic fatty liver disease (NAFLD), which is characterized by hepatic steatosis, can be reversed by early treatment. Several case reports have indicated that the administration of recombinant growth hormone (GH) could improve fatty liver in GH-deficient patients. Here, we investigated whether chronic exogenous GH levels could improve hepatic steatosis induced by a high-fat diet in rats, and explored the underlying mechanisms.

Results: High-fat diet-fed rats developed abdominal obesity, fatty liver and insulin resistance. Chronic exogenous GH improved fatty liver, by reversing dyslipidaemia, fat accumulation and insulin resistance. Exogenous GH also reduced serum tumour necrosis factor-alpha (TNF-alpha) levels, and ameliorated hepatic lipid peroxidation and oxidative stress. Hepatic fat deposition was also reduced by exogenous GH levels, as was the expression of adipocyte-derived adipokines (adiponectin, leptin and resistin), which might improve lipid metabolism and hepatic steatosis. Exogenous GH seems to improve fatty liver by reducing fat weight, improving insulin sensitivity and correcting oxidative stress, which may be achieved through phosphorylation or dephosphorylation of a group of signal transducers and activators of hepatic signal transduction pathways.

Conclusions: Chronic exogenous GH has positive effects on fatty liver and may be a potential clinical application in the prevention or reversal of fatty liver. However, chronic secretion of exogenous GH, even at a low level, may increase serum glucose and insulin levels in rats fed a standard diet, and thus increase the risk of insulin resistance.

Citing Articles

Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.

Dutta D, Nagendra L, Mohindra R, Bhattacharya S, Joshi A, Kamrul-Hasan A Indian J Endocrinol Metab. 2024; 28(4):336-342.

PMID: 39371653 PMC: 11451958. DOI: 10.4103/ijem.ijem_488_23.


Short-Term Growth Hormone Administration Mediates Hepatic Fatty Acid Uptake and De Novo Lipogenesis Gene Expression in Obese Rats.

Likitnukul S, Thammacharoen S, Sriwatananukulkit O, Duangtha C, Hemstapat R, Sunrat C Biomedicines. 2023; 11(4).

PMID: 37189668 PMC: 10135739. DOI: 10.3390/biomedicines11041050.


Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease.

Xue J, Liang S, Ma J, Xiao Y BMC Endocr Disord. 2022; 22(1):49.

PMID: 35216556 PMC: 8881210. DOI: 10.1186/s12902-022-00967-y.


Towards Understanding the Direct and Indirect Actions of Growth Hormone in Controlling Hepatocyte Carbohydrate and Lipid Metabolism.

Vazquez-Borrego M, Del Rio-Moreno M, Kineman R Cells. 2021; 10(10).

PMID: 34685512 PMC: 8533955. DOI: 10.3390/cells10102532.


Effects of the Combination of Evogliptin and Leucine on Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice.

Shin C, Lee H, Kim G, Park S, Choi W, Sohn U Biomol Ther (Seoul). 2021; 29(4):419-426.

PMID: 33814417 PMC: 8255144. DOI: 10.4062/biomolther.2021.003.


References
1.
Shang J, Chen L, Xiao F, Sun H, Ding H, Xiao H . Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin. 2008; 29(6):698-706. DOI: 10.1111/j.1745-7254.2008.00807.x. View

2.
Ikejima K, Okumura K, Lang T, Honda H, Abe W, Yamashina S . The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res. 2005; 33(2):151-4. DOI: 10.1016/j.hepres.2005.09.024. View

3.
Gravholt C, Schmitz O, Simonsen L, Bulow J, Christiansen J, Moller N . Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am J Physiol. 1999; 277(5):E848-54. DOI: 10.1152/ajpendo.1999.277.5.E848. View

4.
BLANE G . Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med. 1987; 83(5B):26-36. DOI: 10.1016/0002-9343(87)90868-0. View

5.
Malendowicz W, Rucinski M, Belloni A, Ziolkowska A, Nussdorfer G, Kwias Z . Real-time PCR analysis of leptin and leptin receptor expression in the rat prostate, and effects of leptin on prostatic acid phosphatase release. Int J Mol Med. 2006; 18(6):1097-100. View